CSTONE PHARMA-B 02616Hong Kong Stock Exchange

5.0902.86%( -0.150 )
Closed: Oct 9 · Delayed · Hong Kong Stock Exchange
CSTONE PHARMA-B (02616) Company Profile - Company Info, Industry & Management - cibo

Company Information

Market
HKEX Main Board
Listing Date
2019-02-26
Industry
Innovative Drugs & Biologics
Fiscal Year End
Dec 31
ISIN
KYG2588M1006

Industry

Innovative Drugs & Biologics 0.02%
124 stocks in this industry
Down 52 Up 57
Industry RankingsValue (HKD)Rank
Revenue (Last FY)316.13M75/112
Net Profit (Last FY)-512.46M109/125
ROE (Last FY)-70.85%98/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition
杨建新 Executive Director
李伟 Non-Executive Director
Kenneth Walton Hitchner III Non-Executive Director
胡正国 Non-Executive Director
Kenneth Howard Jarrett Independent Non-Executive Director
谢芳 Independent Non-Executive Director
严嘉洵 Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2026-01-21.

About this page

This page shows CSTONE PHARMA-B (02616) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.